Soraya Kharboutli
Erlangen, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Universal high-sensitivity CAR T-cell monitoring by targeting linker sequences.
Journal: Frontiers in immunology
Published: January 14, 2026
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.
Journal: Nature medicine
Published: September 30, 2025
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis.
Journal: The New England journal of medicine
Published: September 24, 2025
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus - Authors' reply.
Journal: The Lancet. Rheumatology
Published: July 23, 2025
Long-term follow up of efficiency and safety of CD19-CAR T-cell treatment of systemic lupus erythematosus
Journal: Zeitschrift fur Rheumatologie
Published: July 18, 2025
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study.
Journal: The Lancet. Rheumatology
Published: February 19, 2025
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.
Journal: Nature medicine
Published: January 11, 2025
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
Journal: Blood cancer journal
Published: September 16, 2024
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study.
Journal: HemaSphere
Published: August 17, 2024
Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells.
Journal: Lancet (London, England)
Published: June 21, 2024
Last Updated: 09/26/2026